SIENNA BIOPHARM (NASDAQ:SNNA) posted its quarterly earnings results on Thursday. The company reported ($6.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $5.82, Bloomberg Earnings reports.

Shares of SIENNA BIOPHARM (SNNA) opened at 24.06 on Friday. SIENNA BIOPHARM has a 12-month low of $18.50 and a 12-month high of $29.25. The company’s 50-day moving average is $21.57 and its 200-day moving average is $21.57.

A number of research firms recently weighed in on SNNA. Cowen and Company began coverage on shares of SIENNA BIOPHARM in a report on Monday, August 21st. They set an “outperform” rating and a $50.00 target price on the stock. J P Morgan Chase & Co began coverage on shares of SIENNA BIOPHARM in a report on Monday, August 21st. They set an “overweight” rating and a $28.00 target price on the stock. Finally, BMO Capital Markets began coverage on shares of SIENNA BIOPHARM in a report on Monday, August 21st. They set an “outperform” rating and a $30.00 target price on the stock.

COPYRIGHT VIOLATION NOTICE: “SIENNA BIOPHARM (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $5.82 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/08/sienna-biopharm-snna-releases-quarterly-earnings-results-misses-expectations-by-5-82-eps.html.

In other news, insider Paul F. Lizzul purchased 10,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were acquired at an average price of $15.00 per share, with a total value of $150,000.00. Following the completion of the acquisition, the insider now directly owns 94,634 shares of the company’s stock, valued at $1,419,510. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Richard D. Peterson purchased 7,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $105,000.00. Following the acquisition, the chief financial officer now directly owns 7,000 shares of the company’s stock, valued at $105,000. The disclosure for this purchase can be found here. Insiders have acquired 48,700 shares of company stock worth $730,500 in the last ninety days.

About SIENNA BIOPHARM

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for SIENNA BIOPHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIENNA BIOPHARM and related companies with MarketBeat.com's FREE daily email newsletter.